**Appendix Table E72. Results from studies assessing the ability of Multiplate Analyzer to predict major adverse cardiovascular events in patients with cerebrovascular disease**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author,year****UID****Country****Study name** | **Treatment** | **Phenotypic Test Used [index test]** | **Clinical Outcome** | **Outcome Definition** | **Timing of measurement** | **Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP** | **Outcome status (e.g., bleeding or no bleeding)** | **No. with outcome status within phenotype group** | **Comparative metric (OR, RR, HR)** | **95% CI** | **P (between which groups?)****[statistical test]** | **Adjusted?****[YES/NO/NR]****If YES, for what factors?** | **Procedures for multiple comparisons [YES, NO, NR]** | **Comments (e.g., additional data in figures)** |
| Muller-Schunk, 2008{Muller-Schunk, 2008 175 /id}18223094GermanyNR | LD 300 mg of clopidogrel 75 mg/day continuously | Impedance aggregometry  | Adverse event  | Transient intrainterventional thrombosis, TIA or infarction | NR | Non-responder | Adverse event | 5/14 | OR=42.3 (calculated) | 2.1-833.5 | 0.001 non-responder vs. responderFisher exact test  | NR | NR |  |
|  |  |  |  |  |  | Responder  |  | 0/36 |  |  |  |  |  |  |
|  | LD 300 mg of clopidogrel 75 mg/day continuously  | Impedance aggregometry  | Adverse event  | Transient intrainterventional thrombosis, TIA or infarction | NR | 1 Aggregation unit | Adverse event | NR | OR=1.15 | NR | 0.0321U increase of aggregationlogistic regression  | NR | NR |  |